Goldline Pharmaceutical Limited
ListedSMEHealthcare · BSE
Goldline Pharmaceuticals markets pharmaceutical products under the “Goldline” brand, offering a wide range of medicines across five divisions—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These products cater to various medical specialties including physicians, cardiologists, pediatricians, orthopedics, neurologists, critical care experts, and cancer supportive care. Instead of manufacturing medicines directly, the company works with third-party manufacturers who produce products based on its research and specifications while ensuring quality and regulatory compliance. Goldline sells its products through a network of distributors, retailers, and wholesalers, and also supports hospitals and healthcare providers with procurement and supply services. The company currently partners with 15 manufacturers and 7 distributors, with operations spread across states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Price Band
₹41 – ₹43
Issue Size
₹270.00 L Cr
Lot Size
3000 shares
GMP
₹12
+27.9%
Est. Listing
₹55
at current GMP
Subscribed
840.81x
overall
Open
12 May 2026
Close
14 May 2026
Allotment
15 May 2026
Refund
16 May 2026
Demat Credit
17 May 2026
Listing
19 May 2026
Last updated 4 months ago
Live Grey Market Premium
Goldline Pharmaceutical Limited GMP Today
Last updated: 19 May 2026
Current Premium
₹12+27.9%
Issue Price (Upper)
₹43
Band: ₹41 – ₹43
Estimated Listing Price
₹55
Upper price + GMP
Lot Size
3000 shares
Min investment ₹1,29,000
Estimated Profit / Lot
₹36,000
3000 × ₹12
Goldline Pharmaceutical Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹12
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 28 Sep 2026 | +₹12 | 27.9% | ₹55 |
| 26 Sep 2026 | +₹12 | 27.9% | ₹55 |
| 25 Sep 2026 | +₹11 | 25.1% | ₹54 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Goldline Pharmaceutical Limited Public Issue & Market Profile
Goldline Pharmaceutical Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹27,00,000 Crores. The shares are offered at a price band of ₹41 to ₹43 per equity share on BSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.
Public Issue & Pricing Context:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Basis of Allotment & Listing Timeline:
Following the close of bidding on 2026-05-14, the basis of allotment is scheduled to be finalized on 2026-05-15. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Bigshare Services Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Goldline Pharmaceutical Limited IPO GMP today?
The latest grey market premium for Goldline Pharmaceutical Limited IPO is ₹12, which indicates an expected listing price of ₹55.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.